AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.200
+0.020 (11.11%)
At close: Nov 20, 2024, 4:00 PM
0.197
-0.003 (-1.35%)
After-hours: Nov 20, 2024, 7:58 PM EST
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $35.00K in the quarter ending September 30, 2024, a decrease of -23.91%. This brings the company's revenue in the last twelve months to $190.00K, down -1.55% year-over-year. In the year 2023, AIM ImmunoTech had annual revenue of $202.00K with 43.26% growth.
Revenue (ttm)
$190.00K
Revenue Growth
-1.55%
P/S Ratio
54.99
Revenue / Employee
$6,786
Employees
28
Market Cap
12.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.54M |
Trinity Biotech | 59.13M |
ImmunoPrecise Antibodies | 17.44M |
Sol-Gel Technologies | 11.71M |
Aspira Women's Health | 8.92M |
QT Imaging Holdings | 4.04M |
Immuron | 3.27M |
Talphera | 281.00K |
AIM News
- 1 day ago - AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer - GlobeNewsWire
- 5 days ago - AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 days ago - AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 12 days ago - Aimia Inc. (AIMFF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast - GlobeNewsWire
- 16 days ago - AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - Business Wire
- 6 weeks ago - AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis - GlobeNewsWire
- 7 weeks ago - AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment - GlobeNewsWire